Neuronal M3 Muscarinic Receptors Drive Somatotroph Proliferation; CJC-1295 Rescues Growth Deficit in M3-KO Mice
Background
The precise molecular pathways governing the proliferation and maintenance of pituitary somatotrophs and other anterior pituitary cells remain largely undefined. This knowledge gap hinders the development of novel therapeutics for various human growth disorders. While muscarinic cholinergic pathways have been implicated in regulating somatotroph function, the specific receptor subtypes and physiological relevance of these effects have been unclear. This study aimed to elucidate the role of specific muscarinic acetylcholine receptor subtypes in pituitary development and somatic growth, addressing a critical gap in understanding growth regulation.
Study Design
Researchers investigated the role of M3 muscarinic acetylcholine receptors (M3R) using mutant mice selectively lacking the M3R subtype in the brain (Br-M3-KO mice), encompassing both neuronal and glial cells. They characterized the phenotype of these Br-M3-KO mice, focusing on growth parameters and pituitary morphology. Subsequently, they treated Br-M3-KO mice with CJC-1295, a synthetic growth hormone-releasing hormone (GHRH) analog, to assess its ability to rescue observed growth deficits. The study also included M3 receptor/GHRH colocalization studies and hypothalamic hormone measurements to understand the underlying mechanisms.
Results
Br-M3-KO mice exhibited a pronounced dwarf phenotype, characterized by a significant hypoplasia of the anterior pituitary gland. These mutant mice also showed a marked decrease in both pituitary and serum growth hormone (GH) and prolactin levels. This indicated a critical role for central M3R in regulating pituitary function and overall somatic growth. Remarkably, treatment of Br-M3-KO mice with CJC-1295, a synthetic GHRH analog, effectively rescued the observed growth deficit. > CJC-1295 treatment restored normal pituitary size and normalized serum GH and IGF-1 levels in the Br-M3-KO mice, demonstrating its therapeutic potential. These findings, supported by M3 receptor/GHRH colocalization studies and hypothalamic hormone measurements, strongly suggest that central (hypothalamic) M3 receptors are essential for the proper function of hypothalamic GHRH neurons, thereby promoting the proliferation of pituitary somatotroph cells and regulating longitudinal growth.
Key Findings
- Br-M3-KO mice exhibited a dwarf phenotype and pronounced anterior pituitary hypoplasia.
- Pituitary and serum GH and prolactin levels were markedly decreased in Br-M3-KO mice.
- CJC-1295 treatment rescued the growth deficit in Br-M3-KO mice.
- CJC-1295 restored normal pituitary size and normalized serum GH and IGF-1 levels.
- Central M3 receptors are required for proper hypothalamic GHRH neuron function.
Why It Matters
This research reveals a fundamental, previously unrecognized role for neuronal M3 muscarinic acetylcholine receptors in regulating somatic growth and pituitary somatotroph proliferation. For individuals with growth disorders stemming from pituitary dysfunction, this opens new avenues for therapeutic intervention, potentially targeting M3R pathways or leveraging GHRH analogs. The successful rescue of growth deficits with CJC-1295 in M3-KO mice highlights its potential as a clinical strategy for growth hormone deficiency, even when the underlying cause involves central muscarinic receptor dysfunction. This suggests that GHRH analogs could bypass specific upstream signaling defects, offering a practical approach to restoring normal growth and hormone levels.
m3-muscarinic-receptor
cjc-1295
growth-hormone
somatotrophs
pituitary
growth-disorder